Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Role of Plasma PAI-1 in American Indians Evaluated
J Thromb Haemost; ePub 2017 May 3; Peng, et al
Plasminogen activator inhibitor-1 (PAI-1) level was linked with shorter leukocyte telomere length (LTL) in American Indians in a study involving more than 2,500 individuals.
Investigators measured LTL and plasma PAI-1 in American Indians who were part of the Strong Heart Family Study (SHFS) clinical examination from 2001–2003. They also took these measures in 475 of the participants who attended SHFS clinical visits in both 2001–2003 and 1998–1999. Among the results:
- Higher level of plasma PAI-1 was negatively linked with shorter age-adjusted LTL.
- This link was weakened after adjusting for demographics, study site, lifestyle, and metabolic factors.
- Longitudinal analysis revealed that change in plasma PAI-1 was also inversely linked with change in LTL after adjusting for demographics, follow-up years, lifestyle factors, changes in metabolic factors, baseline levels of PAI-1 and LTL.
The authors noted that their findings suggest a potential role of PAI-1 in biological aging among American Indians.
Peng H, Yeh F, Lin J, et al. Plasminogen activator inhibitor-1 is associated with leukocyte telomere length in American Indians: Findings from the Strong Heart Family Study. [Published online ahead of print May 3, 2017]. J Thromb Haemost. doi:10.1111/jth.13689.